New opportunities for field research on the pathogenesis and treatment of Lassa fever

Antiviral Research

Volumn 78, Issue 1, 2008, Pages 103-115

  Khan, Sheik Humarr ^a,b   Goba, Augustine ^a,b   Chu, May ^c   Roth, Cathy ^c   Healing, Tim ^c   Marx, Arthur ^c   Fair, Joseph ^b,d   Guttieri, Mary C ^d   Ferro, Philip ^d   Imes, Tiffany ^b   Monagin, Corina ^b   Garry, Robert F ^b   Bausch, Daniel G ^b  

^a Kenema Government Hospital   (Sierra Leone)

^b TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^c WORLD HEALTH ORGANIZATION   (Switzerland)

^d UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

Author keywords

Antiviral therapy; Arenavirus; Lassa fever; Lassa virus; Pathogenesis; Ribavirin; Viral hemorrhagic fever; West Africa

Indexed keywords

CONSENSUS INTERFERON; DNA VACCINE; DROTRECOGIN; RIBAVIRIN; SMALL INTERFERING RNA;

ARTICLE; BRAIN HEMORRHAGE; CLINICAL FEATURE; CLINICAL TRIAL; CONTINUOUS INFUSION; EPIDEMIC; GUINEA; HEMOLYTIC ANEMIA; HEMORRHAGIC FEVER; HUMAN; INCIDENCE; INFECTION PREVENTION; LASSA FEVER; LASSA VIRUS; LIBERIA; MEDICAL RESEARCH; NAUSEA; NONHUMAN; PRIORITY JOURNAL; SIERRA LEONE; VIRUS PATHOGENESIS; VOMITING;

ADOLESCENT; ADULT; AFRICA, WESTERN; ANTIVIRAL AGENTS; CHILD, PRESCHOOL; FEMALE; HUMANS; INCIDENCE; INFANT, NEWBORN; LASSA FEVER; LASSA VIRUS; MALE; PREGNANCY; RESEARCH; RIBAVIRIN;

ARENAVIRUS; LASSA VIRUS;

EID: 40749093780     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.antiviral.2007.11.003     Document Type: Article

References (114)

1. Anon. Management of patients with suspected viral hemorrhagic fever. MMWR Morb. Mortal Wkly. Rep. 37 Suppl. 3 (1988) 1-16
2. Anon. Update: management of patients with suspected viral hemorrhagic fever-United States. MMWR Morb. Mortal Wkly. Rep. 44 (1995) 475-479
3. Anon. Outbreak of Marburg virus hemorrhagic fever-Angola, October 1, 2004-March 29, 2005. MMWR Morb. Mortal Wkly. Rep. 54 (2005) 308-309
4. Aronson J.F., Herzog N.K., and Jerrells T.R. Tumor necrosis factor and the pathogenesis of Pichinde virus infection in guinea pigs. Am. J. Trop. Med. Hyg. 52 (1995) 262-269
5. Asper M., Sternsdorf T., Hass M., Drosten C., Rhode A., Schmitz H., and Gunther S. Inhibition of different Lassa virus strains by alpha and gamma interferons and comparison with a less pathogenic arenavirus. J. Virol. 78 (2004) 3162-3169
6. Baize S., Pannetier D., Faure C., Marianneau P., Marendat I., Georges-Courbot M.C., and Deubel V. Role of interferons in the control of Lassa virus replication in human dendritic cells and macrophages. Microb. Infect. 8 (2006) 1194-1202
7. Bausch, D.G., 2007. In: Goldmann, D. (Ed.), Ebola and Marburg Viruses. Physicians' Information and Education Resource. American College of Physicians, Philadelphia, PA. Online publication: http://pier.acponline.org/physicians/diseases/d891/d891.html.
8. Bausch D.G., Demby A.H., Coulibaly M., Kanu J., Goba A., Bah A., Conde N., Wurtzel H.L., Cavallaro K.F., Lloyd E., Baldet F.B., Cisse S.D., Fofona D., Savane I.K., Tolno R.T., Mahy B., Wagoner K.D., Ksiazek T.G., Peters C.J., and Rollin P.E. Lassa fever in Guinea: I. Epidemiology of human disease and clinical observations. Vector Borne Zoon. Dis. 1 (2001) 269-281
9. Bausch D.G., Nichol S.T., Muyembe-Tamfum J.J., Borchert M., Rollin P.E., Sleurs H., Campbell P., Tshioko F.K., Roth C., Colebunders R., Pirard P., Mardel S., Olinda L.A., Zeller H., Tshomba A., Kulidri A., Libande M.L., Mulangu S., Formenty P., Grein T., Leirs H., Braack L., Ksiazek T., Zaki S., Bowen M.D., Smit S.B., Leman P.A., Burt F.J., Kemp A., and Swanepoel R. Marburg hemorrhagic fever associated with multiple genetic lineages of virus. N. Engl. J. Med. 355 (2006) 909-919
10. Bausch D.G., Rollin P.E., Demby A.H., Coulibaly M., Kanu J., Conteh A.S., Wagoner K.D., McMullan L.K., Bowen M.D., Peters C.J., and Ksiazek T.G. Diagnosis and clinical virology of Lassa fever as evaluated by enzyme-linked immunosorbent assay, indirect fluorescent-antibody test, and virus isolation. J. Clin. Microbiol. 38 (2000) 2670-2677
11. Bausch D.G., Sesay S.S., and Oshin B. On the front lines of Lassa fever: Aniru Conteh (1942-2004) [Obituary]. Emerg. Infect. Dis. 10 (2004) 1889-1890
12. Bergthaler A., Gerber N.U., Merkler D., Horvath E., de la Torre J.C., and Pinschewer D.D. Envelope exchange for the generation of live-attenuated arenavirus vaccines. PLoS Pathog. 2 (2006) e51
13. Bernard G.R., Macias W.L., Joyce D.E., Williams M.D., Bailey J., and Vincent J.L. Safety assessment of drotrecogin alfa (activated) in the treatment of adult patients with severe sepsis. Crit. Care 7 (2003) 155-163
14. Bernard G.R., Vincent J.L., Laterre P.F., LaRosa S.P., Dhainaut J.F., Lopez-Rodriguez A., Steingrub J.S., Garber G.E., Helterbrand J.D., Ely E.W., and Fisher Jr. C.J. Efficacy and safety of recombinant human activated protein C for severe sepsis. N. Engl. J. Med. 344 (2001) 699-709
15. Bloch A. A serological survey of Lassa fever in Liberia. Bull. World Health Org. 56 (1978) 811-813
16. Bossi P., Tegnell A., Baka A., Van Loock F., Hendriks J., Werner A., Maidhof H., and Gouvras G. Bichat guidelines for the clinical management of haemorrhagic fever viruses and bioterrorism-related haemorrhagic fever viruses. Eur. Surveill. 9 (2004) E11-E12
17. Bowen M.D., Rollin P.E., Ksiazek T.G., Hustad H.L., Bausch D.G., Demby A.H., Bajani M.D., Peters C.J., and Nichol S.T. Genetic diversity among Lassa virus strains. J. Virol. 74 (2000) 6992-7004
18. Bredenbeek P.J., Molenkamp R., Spaan W.J., Deubel V., Marianneau P., Salvato M.S., Moshkoff D., Zapata J., Tikhonov I., Patterson J., Carrion R., Ticer A., Brasky K., and Lukashevich I.S. A recombinant Yellow Fever 17D vaccine expressing Lassa virus glycoproteins. Virology 345 (2006) 299-304
19. Brummel-Ziedins K., Whelihan M.F., Ziedins E.G., and Mann K.G. The resuscitative fluid you choose may potentiate bleeding. J. Trauma 61 (2006) 1350-1358
20. Buckley S.M., and Casals J. Lassa fever, a new virus disease of man from West Africa. III. Isolation and characterization of the virus. Am. J. Trop. Med. Hyg. 19 (1970) 680-691
21. Callis R.T., Jahrling P.B., and DePaoli A. Pathology of Lassa virus infection in the rhesus monkey. Am. J. Trop. Med. Hyg. 31 (1982) 1038-1045
22. Carey D.E., Kemp G.E., White H.A., Pinneo L., Addy R.F., Fom A.L., Stroh G., Casals J., and Henderson B.E. Lassa fever. Epidemiological aspects of the 1970 epidemic, Jos, Nigeria. Trans. R. Soc. Trop. Med. Hyg. 66 (1972) 402-408
23. Carrion Jr. R., Patterson J.L., Johnson C., Gonzales M., Moreira C.R., Ticer A., Brasky K., Hubbard G.B., Moshkoff D., Zapata J., Salvato M.S., and Lukashevich I.S. A ML29 reassortant virus protects guinea pigs against a distantly related Nigerian strain of Lassa virus and can provide sterilizing immunity. Vaccine 25 (2007) 4093-4102
24. CDC and WHO. Infection Control for Viral Haemorrhagic Fevers in the African Health Care Setting (1998), Centers for Disease Control and Prevention, Atlanta
25. Chapman, L.E., Mertz, G.J., Peters, C.J., Jolson, H.M., Khan, A.S., Ksiazek, T.G., Koster, F.T., Baum, K.F., Rollin, P.E., Pavia, A.T., Holman, R.C., Christenson, J.C., Rubin, P.J., Behrman, R.E., Bell, L.J., Simpson, G.L., Sadek, R.F., 1999. Intravenous ribavirin for hantavirus pulmonary syndrome: safety and tolerance during 1 year of open-label experience. Ribavirin Study Group. Antivir. Ther. 4, 211-219.
26. Connor J.D., Hintz M., Van Dyke R., McCormick J.B., and McIntosh K. Ribavirin Pharmacokinetics in Children and Adults During Therapeutic Trials (1984), Academic Press, Inc., Orlando, FL
27. Crowcroft N.S. Management of Lassa fever in European countries. Eur. Surveill. 7 (2002) 50-52
28. Cummins D. Lassa fever. Br. J. Hosp. Med. 43 (1990) 186-188, 190, 192
29. Cummins D., Bennett D., Fisher-Hoch S.P., Farrar B., and McCormick J.B. Electrocardiographic abnormalities in patients with Lassa fever. J. Trop. Med. Hyg. 92 (1989) 350-355
30. Cummins D., Fisher-Hoch S.P., Walshe K.J., Mackie I.J., McCormick J.B., Bennett D., Perez G., Farrar B., and Machin S.J. A plasma inhibitor of platelet aggregation in patients with Lassa fever. Br. J. Haematol. 72 (1989) 543-548
31. Cummins D., McCormick J.B., Bennett D., Samba J.A., Farrar B., Machin S.J., and Fisher-Hoch S.P. Acute sensorineural deafness in Lassa fever. JAMA 264 (1990) 2093-2096
32. Demby A.H., Inapogui A., Kargbo K., Koninga J., Kourouma K., Kanu J., Coulibaly M., Wagoner K.D., Ksiazek T.G., Peters C.J., Rollin P.E., and Bausch D.G. Lassa fever in Guinea: II. Distribution and prevalence of Lassa virus infection in small mammals. Vect. Bor. Zoon. Dis. 1 (2001) 283-297
33. Djavani M.M., Crasta O.R., Zapata J.C., Fei Z., Folkerts O., Sobral B., Swindells M., Bryant J., Davis H., Pauza C.D., Lukashevich I.S., Hammamieh R., Jett M., and Salvato M.S. Early blood profiles of virus infection in a monkey model for Lassa fever. J. Virol. 81 (2007) 7960-7973
34. Enria D., Mills J.N., Flick R., Bowen M.D., Bausch D., Shieh W., and Peters C.J. Arenavirus infections. In: Guerrant R.L., et al. (Ed). Tropical Infectious Diseases: Principles, Pathogens, & Practice vol. 1 (2006), Elsevier, Philadelphia, PA 734-755
35. Fair J., Jentes E., Inapogui A., Kourouma K., Goba A., Bah A., Tounkara M., Coulibaly M., Garry R.F., and Bausch D.G. Lassa virus-infected rodents in refugee camps in Guinea: a looming threat to public health in a politically unstable region. Vect. Bor. Zoon. Dis. 7 (2007) 167-172
36. Feistritzer C., and Wiedermann C.J. Effects of anticoagulant strategies on activation of inflammation and coagulation. Exp. Opin Biol. Ther. 7 (2007) 855-870
37. Fennewald S.M., Aronson J.F., Zhang L., and Herzog N.K. Alterations in NF-kappaB and RBP-Jkappa by arenavirus infection of macrophages in vitro and in vivo. J. Virol. 76 (2002) 1154-1162
38. Fichet-Calvet E., Lecompte E., Koivogui L., Soropogui B., Dore A., Kourouma F., Sylla O., Daffis S., Koulemou K., and Ter Meulen J. Fluctuation of Abundance and Lassa Virus Prevalence in Mastomys natalensis in Guinea. West Afr. Vect. Bor. Zoon. Dis. 7 (2007) 119-128
39. Fisher-Hoch S., McCormick J.B., Sasso D., and Craven R.B. Hematologic dysfunction in Lassa fever. J. Med. Virol. 26 (1988) 127-135
40. Fisher-Hoch S.P., Gborie S., Parker L., and Huggins J. Unexpected adverse reactions during a clinical trial in rural West Africa. Antivir. Res. 19 (1992) 139-147
41. Fisher-Hoch S.P., Price M.E., Craven R.B., Price F.M., Forthall D.N., Sasso D.R., Scott S.M., and McCormick J.B. Safe intensive-care management of a severe case of Lassa fever with simple barrier nursing techniques. Lancet 2 (1985) 1227-1229
42. Fisher-Hoch S.P., Tomori O., Nasidi A., Perez-Oronoz G.I., Fakile Y., Hutwagner L., and McCormick J.B. Review of cases of nosocomial Lassa fever in Nigeria: the high price of poor medical practice. BMJ 311 (1995) 857-859
43. Frame J.D. Clinical features of Lassa fever in Liberia. Rev. Infect. Dis. 11 Suppl. 4 (1989) S783-S789
44. Frame J.D., Baldwin Jr. J.M., Gocke D.J., and Troup J.M. Lassa fever, a new virus disease of man from West Africa. I. Clinical description and pathological findings. Am. J. Trop. Med. Hyg. 19 (1970) 670-676
45. Frame J.D., Casals J., and Dennis E.A. Lassa virus antibodies in hospital personnel in western Liberia. Trans. R. Soc. Trop. Med. Hyg. 73 (1979) 219-224
46. Frame J.D., Jahrling P.B., Yalley-Ogunro J.E., and Monson M.H. Endemic Lassa fever in Liberia. II. Serological and virological findings in hospital patients. Trans. R. Soc. Trop. Med. Hyg. 78 (1984) 656-660
47. Frame J.D., Yalley-Ogunro J.E., and Hanson A.P. Endemic Lassa fever in Liberia. V. Distribution of Lassa virus activity in Liberia: hospital staff surveys. Trans. R. Soc. Trop. Med. Hyg. 78 (1984) 761-763
48. Fraser D.W., Campbell C.C., Monath T.P., Goff P.A., and Gregg M.B. Lassa fever in the Eastern Province of Sierra Leone, 1970-1972. I. Epidemiologic studies. Am. J. Trop. Med. Hyg. 23 (1974) 1131-1139
49. Geisbert T.W., Jones S., Fritz E.A., Shurtleff A.C., Geisbert J.B., Liebscher R., Grolla A., Stroher U., Fernando L., Daddario K.M., Guttieri M.C., Mothe B.R., Larsen T., Hensley L.E., Jahrling P.B., and Feldmann H. Development of a new vaccine for the prevention of Lassa fever. PLoS Med. 2 (2005) e183
50. Gowen B.B., and Holbrook M.R. Animal models of highly pathogenic RNA viral infections: hemorrhagic fever viruses. Antivir. Res. 78 (2008) 79-90
51. Gowen B.B., Smee D.F., Wong M.H., Pace A.M., Jung K.H., Bailey K.W., Blatt L.M., and Sidwell R.W. Combinatorial ribavirin and interferon alfacon-1 therapy of acute arenaviral disease in hamsters. Antivir. Chem. Chemother. 17 (2006) 175-183
52. Gunther S., Weisner B., Roth A., Grewing T., Asper M., Drosten C., Emmerich P., Petersen J., Wilczek M., and Schmitz H. Lassa fever encephalopathy: Lassa virus in cerebrospinal fluid but not in serum. J. Infect. Dis. 184 (2001) 345-349
53. Guo Z.M., Liu C.T., and Peters C.J. Possible involvement of endogenous beta-endorphin in the pathophysiological mechanisms of Pichinde virus-infected guinea pigs. Proc. Soc. Exp. Biol. Med. 200 (1992) 343-348
54. Guo Z.M., Qian C., Peters C.J., and Liu C.T. Changes in platelet-activating factor, catecholamine, and serotonin concentrations in brain, cerebrospinal fluid, and plasma of Pichinde virus-infected guinea pigs. Lab. Anim. Sci. 43 (1993) 569-574
55. Haas W.H., Breuer T., Pfaff G., Schmitz H., Kohler P., Asper M., Emmerich P., Drosten C., Golnitz U., Fleischer K., and Gunther S. Imported Lassa fever in Germany: surveillance and management of contact persons. Clin. Infect. Dis. 36 (2003) 1254-1258
56. Hadi, C.M., Sankoh, M., Koroma, S., Juana, B., Goba, A., Bah, A., Coulibaly, M., Lertora, J.J., Bausch, D.G. Ribavirin post-exposure prophylaxis for Lassa fever: study of adherence and adverse effects, review of the literature, and proposed guidelines for use, manuscript in preparation.
57. Hass M., Golnitz U., Muller S., Becker-Ziaja B., and Gunther S. Replicon system for Lassa virus. J. Virol. 78 (2004) 13793-13803
58. Hirabayashi Y., Oka S., Goto H., Shimada K., Kurata T., Fisher-Hoch S.P., and McCormick J.B. An imported case of Lassa fever with late appearance of polyserositis. J. Infect. Dis. 158 (1988) 872-875
59. Holmes G.P., McCormick J.B., Trock S.C., Chase R.A., Lewis S.M., Mason C.A., Hall P.A., Brammer L.S., Perez-Oronoz G.I., and McDonnell M.K. Lassa fever in the United States. Investigation of a case and new guidelines for management. N. Engl. J. Med. 323 (1990) 1120-1123
60. Huggins J.W. Prospects for treatment of viral hemorrhagic fevers with ribavirin, a broad-spectrum antiviral drug. Rev. Infect. Dis. 11 Suppl 4 (1989) S750-S761
61. Huggins J.W., Jahrling P.B., Kende M., and Canonico P.G. Efficacy of ribavirin against virulent RNA virus infections. In: Smith R.A., et al. (Ed). Clinical Applications of Ribavirin (1984), Academic Press, New York 49-63
62. Ikerionwu S.E., Sato K., Katchy K.C., and Suseelan A.A. Lassa fever-an autopsy report from the eastern part of Nigeria. J. Trop. Med. Hyg. 81 (1978) 134-136
63. Jahrling P.B., Frame J.D., Rhoderick J.B., and Monson M.H. Endemic Lassa fever in Liberia. IV. Selection of optimally effective plasma for treatment by passive immunization. Trans. R. Soc. Trop. Med. Hyg. 79 (1985) 380-384
64. Jahrling P.B., Frame J.D., Smith S.B., and Monson M.H. Endemic Lassa fever in Liberia. III. Characterization of Lassa virus isolates. Trans. R. Soc. Trop. Med. Hyg. 79 (1985) 374-379
65. Jahrling P.B., Hesse R.A., Eddy G.A., Johnson K.M., Callis R.T., and Stephen E.L. Lassa virus infection of rhesus monkeys: pathogenesis and treatment with ribavirin. J. Infect. Dis. 141 (1980) 580-589
66. Johnson K. Lassa fever: life saving therapy with ribavirin. In: Stapleton T. (Ed). Studies with Broad-Spectrum Antiviral Agent vol. 108 (1986), Royal Society of Medicine Services, London, New York 25-36
67. Johnson K.M., McCormick J.B., Webb P.A., Smith E.S., Elliott L.H., and King I.J. Clinical virology of Lassa fever in hospitalized patients. J. Infect. Dis. 155 (1987) 456-464
68. Johnson K.M., and Monath T.P. Imported Lassa fever-re-examining the algorithms. N. Engl. J. Med. 323 (1990) 1139-1141
69. Ketai L., Alrahji A.A., Hart B., Enria D., and Mettler Jr. F. Radiologic manifestations of potential bioterrorist agents of infection. AJR Am. J. Roentgenol. 180 (2003) 565-575
70. Knobloch J., Albiez E., and Schmitz H. A Serological survey on viral haemorrhagic fevers in Liberia. Annal. Virol. 133 (1982) 125-128
71. Knobloch J., McCormick J.B., Webb P.A., Dietrich M., Schumacher H.H., and Dennis E. Clinical observations in 42 patients with Lassa fever. Tropenmed. Parasitol. 31 (1980) 389-398
72. Lange J.V., Mitchell S.W., McCormick J.B., Walker D.H., Evatt B.L., and Ramsey R.R. Kinetic study of platelets and fibrinogen in Lassa virus-infected monkeys and early pathologic events in Mopeia virus-infected monkeys. Am. J. Trop. Med. Hyg. 34 (1985) 999-1007
73. Liao B.S., Byl F.M., and Adour K.K. Audiometric comparison of Lassa fever hearing loss and idiopathic sudden hearing loss: evidence for viral cause. Otolaryngol. Head Neck Surg. 106 (1992) 226-229
74. Liu C.T., Jahrling P.B., and Peters C.J. Evidence for the involvement of sulfidopeptide leukotrienes in the pathogenesis of Pichinde virus infection in strain 13 guinea pigs. Prostagland. Leukot. Med. 24 (1986) 129-138
75. Lukashevich I.S., Patterson J., Carrion R., Moshkoff D., Ticer A., Zapata J., Brasky K., Geiger R., Hubbard G.B., Bryant J., and Salvato M.S. A live attenuated vaccine for Lassa fever made by reassortment of Lassa and Mopeia viruses. J. Virol. 79 (2005) 13934-13942
76. Lukashevich L.S., Clegg J.C., and Sidibe K. Lassa virus activity in Guinea: Distribution of human antiviral antibody defined using enzyme-linked immunosorbent assay with recombinant antigen. J. Med. Virol. 40 (1993) 210-217
77. Mahanty S., Bausch D.G., Thomas R.L., Goba A., Bah A., Peters C.J., and Rollin P.E. Low levels of interleukin-8 and interferon-inducible protein-10 in serum are associated with fatal infections in acute Lassa fever. J. Infect. Dis. 183 (2001) 1713-1721
78. McCormick J.B., King I.J., Webb P.A., Scribner C.L., Craven R.B., Johnson K.M., Elliott L.H., and Belmont-Williams R. Lassa fever. Effective therapy with ribavirin. N. Engl. J. Med. 314 (1986) 20-26
79. McCormick J.B., King I.J., Webb P.A., Johnson K.M., O'Sullivan R., Smith E.S., Trippel S., and Tong T.C. A case-control study of the clinical diagnosis and course of Lassa fever. J. Infect. Dis. 155 (1987) 445-455
80. McCormick J.B., Webb P.A., Krebs J.W., Johnson K.M., and Smith E.S. A prospective study of the epidemiology and ecology of Lassa fever. J. Infect. Dis. 155 (1987) 437-444
81. Mertens P.E., Patton R., Baum J.J., and Monath T.P. Clinical presentation of Lassa fever cases during the hospital epidemic at Zorzor, Liberia, March-April 1972. Am. J. Trop. Med. Hyg. 22 (1973) 780-784
82. Monath T.P., Maher M., Casals J., Kissling R.E., and Cacciapuoti A. Lassa fever in the Eastern Province of Sierra Leone, 1970-1972. II. Clinical observations and virological studies on selected hospital cases. Am. J. Trop. Med. Hyg. 23 (1974) 1140-1149
83. Monath T.P., Mertens P.E., Patton R., Moser C.R., Baum J.J., Pinneo L., Gary G.W., and Kissling R.E. A hospital epidemic of Lassa fever in Zorzor, Liberia, March-April 1972. Am. J. Trop. Med. Hyg. 22 (1973) 773-779
84. Monath T.P., Newhouse V.F., Kemp G.E., Setzer H.W., and Cacciapuoti A. Lassa virus isolation from Mastomys natalensis rodents during an epidemic in Sierra Leone. Science 185 (1974) 263-265
85. Monson M.H., Cole A.K., Frame J.D., Serwint J.R., Alexander S., and Jahrling P.B. Pediatric Lassa fever: a review of 33 Liberian cases. Am. J. Trop. Med. Hyg. 36 (1987) 408-415
86. Monson M.H., Frame J.D., Jahrling P.B., and Alexander K. Endemic Lassa fever in Liberia. I. Clinical and epidemiological aspects at Curran Lutheran Hospital, Zorzor, Liberia. Trans. R. Soc. Trop. Med. Hyg. 78 (1984) 549-553
87. Muller S., and Gunther S. Broad-spectrum antiviral activity of small interfering RNA targeting the conserved RNA termini of Lassa virus. Antimicrob. Agents Chemother. 51 (2007) 2215-2218
88. Peters C.J., Jahrling P.B., Liu C.T., Kenyon R.H., McKee Jr. K.T., and Barrera Oro J.G. Experimental studies of arenaviral hemorrhagic fevers. Curr. Top. Microbiol. Immunol. 134 (1987) 5-68
89. Peters C.J., Liu C.T., Anderson Jr. G.W., Morrill J.C., and Jahrling P.B. Pathogenesis of viral hemorrhagic fevers: Rift Valley fever and Lassa fever contrasted. Rev. Infect. Dis. 11 Suppl 4 (1989) S743-S749
90. Price M.E., Fisher-Hoch S.P., Craven R.B., and McCormick J.B. A prospective study of maternal and fetal outcome in acute Lassa fever infection during pregnancy. BMJ 297 (1988) 584-587
91. Pushko P., Geisbert J., Parker M., Jahrling P., and Smith J. Individual and bivalent vaccines based on alphavirus replicons protect guinea pigs against infection with Lassa and Ebola viruses. J. Virol. 75 (2001) 11677-11685
92. Qian C., Jahrling P.B., Peters C.J., and Liu C.T. Cardiovascular and pulmonary responses to Pichinde virus infection in strain 13 guinea pigs. Lab. Anim. Sci. 44 (1994) 600-607
93. Qian C., Liu C.T., and Peters C.J. Metabolism of platelet-activating factor in neutrophils isolated from Pichinde virus-infected guinea pigs. J. Leukoc. Biol. 51 (1992) 210-213
94. Rivers E., Nguyen B., Havstad S., Ressler J., Muzzin A., Knoblich B., Peterson E., and Tomlanovich M. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N. Engl. J. Med. 345 (2001) 1368-1377
95. Roberts P.J., Cummins D., Bainton A.L., Walshe K.J., Fisher-Hoch S.P., McCormick J.B., Gribben J.G., Machin S.J., and Linch D.C. Plasma from patients with severe Lassa fever profoundly modulates f-met-leu-phe induced superoxide generation in neutrophils. Br. J. Haematol. 73 (1989) 152-157
96. Rodriguez-Carreno M.P., Nelson M.S., Botten J., Smith-Nixon K., Buchmeier M.J., and Whitton J.L. Evaluating the immunogenicity and protective efficacy of a DNA vaccine encoding Lassa virus nucleoprotein. Virology 335 (2005) 87-98
97. Sanchez A.B., Perez M., Cornu T., and de la Torre J.C. RNA interference-mediated virus clearance from cells both acutely and chronically infected with the prototypic arenavirus lymphocytic choriomeningitis virus. J. Virol. 79 (2005) 11071-11081
98. Schmitz H., Kohler B., Laue T., Drosten C., Veldkamp P.J., Gunther S., Emmerich P., Geisen H.P., Fleischer K., Beersma M.F., and Hoerauf A. Monitoring of clinical and laboratory data in two cases of imported Lassa fever. Microb. Infect. 4 (2002) 43-50
99. Schuler A. Billions for biodefense: federal agency biodefense budgeting, FY2005-FY2006. Biosecur. Bioterror. 3 (2005) 94-101
100. Solbrig M. Lassa virus and central nervous system diseases. In: Salvato M. (Ed). The Arenaviridae (1993), Plenum Press, New York 325-330
101. Solbrig M.V., and McCormick J.B. Lassa fever: central nervous system manifestations. J. Trop. Geograph. Neurol. 1 (1991) 23-30
102. ter Meulen J., Koulemou K., Wittekindt T., Windisch K., Strigl S., Conde S., and Schmitz H. Detection of Lassa virus antinucleoprotein immunoglobulin G (IgG) and IgM antibodies by a simple recombinant immunoblot assay for field use. J. Clin. Microbiol. 36 (1998) 3143-3148
103. ter Meulen J., Lukashevich I., Sidibe K., Inapogui A., Marx M., Dorlemann A., Yansane M.L., Koulemou K., Chang-Claude J., and Schmitz H. Hunting of peridomestic rodents and consumption of their meat as possible risk factors for rodent-to-human transmission of Lassa virus in the Republic of Guinea. Am. J. Trop. Med. Hyg. 55 (1996) 661-666
104. Troup J.M., White H.A., Fom A.L., and Carey D.E. An outbreak of Lassa fever on the Jos plateau, Nigeria, in January-February 1970. A preliminary report. Am. J. Trop. Med. Hyg. 19 (1970) 695-696
105. Uckun, F.M., Petkevich, A.S., Vassilev, A.O., Tibbles, H.E., Titov, L., 2004. Stampidine prevents mortality in an experimental mouse model of viral hemorrhagic fever caused by Lassa virus. BMC Infect. Dis. 4, 1.
106. Uckun F.M., Venkatachalam T.K., Erbeck D., Chen C.L., Petkevich A.S., and Vassilev A. Zidampidine, an aryl phosphate derivative of AZT: in vivo pharmacokinetics, metabolism, toxicity, and anti-viral efficacy against hemorrhagic fever caused by Lassa virus. Bioorg. Med. Chem. 13 (2005) 3279-3288
107. Van den Berghe G., Wouters P., Weekers F., Verwaest C., Bruyninckx F., Schetz M., Vlasselaers D., Ferdinande P., Lauwers P., and Bouillon R. Intensive insulin therapy in the critically ill patients. N. Engl. J. Med. 345 (2001) 1359-1367
108. Van der Waals F.W., Pomeroy K.L., Goudsmit J., Asher D.M., and Gajdusek D.C. Hemorrhagic fever virus infections in an isolated rainforest area of central Liberia. Limitations of the indirect immunofluorescence slide test for antibody screening in Africa. Trop. Geogr. Med. 38 (1986) 209-214
109. Vincent J.L., Bernard G.R., Beale R., Doig C., Putensen C., Dhainaut J.F., Artigas A., Fumagalli R., Macias W., Wright T., Wong K., Sundin D.P., Turlo M.A., and Janes J. Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: further evidence for survival and safety and implications for early treatment. Crit. Care Med. 33 (2005) 2266-2277
110. Walker D.H., McCormick J.B., Johnson K.M., Webb P.A., Komba-Kono G., Elliott L.H., and Gardner J.J. Pathologic and virologic study of fatal Lassa fever in man. Am. J. Pathol. 107 (1982) 349-356
111. Webb P.A., McCormick J.B., King I.J., Bosman I., Johnson K.M., Elliott L.H., Kono G.K., and O'Sullivan R. Lassa fever in children in Sierra Leone, West Africa. Trans. R. Soc. Trop. Med. Hyg. 80 (1986) 577-582
112. WHO, 2005. Update on Lassa fever in West Africa, WHO Wkly. Epidemiol. Rec., 80 (10), 86-88.
113. Yalley-Ogunro J.E., Frame J.D., and Hanson A.P. Endemic Lassa fever in Liberia. VI. Village serological surveys for evidence of Lassa virus activity in Lofa County, Liberia. Trans. R. Soc. Trop. Med. Hyg. 78 (1984) 764-770
114. Yanase O., Motomiya T., Watanabe K., Tokuyasu Y., Sakurada H., Tejima T., Hiyoshi Y., Sugiura M., Yabata Y., and Kitazumi H. Lassa fever associated with effusive constrictive pericarditis and bilateral atrioventricular annular constriction: a case report. J. Cardiol. 19 (1989) 1147-1156